Cargando…

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

PURPOSE: The prostate-specific membrane antigen (PSMA) has emerged as an interesting target for radionuclide therapy of metastasized castration-resistant prostate cancer (mCRPC). The aim of this study was to investigate (161)Tb (T(1/2) = 6.89 days; Eβ(-)uperscript>(av) = 154 keV) in combination w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müller, Cristina, Umbricht, Christoph A., Gracheva, Nadezda, Tschan, Viviane J., Pellegrini, Giovanni, Bernhardt, Peter, Zeevaart, Jan Rijn, Köster, Ulli, Schibli, Roger, van der Meulen, Nicholas P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6820371/ https://www.ncbi.nlm.nih.gov/pubmed/31134301 http://dx.doi.org/10.1007/s00259-019-04345-0

Ejemplares similares

Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy
por: Gracheva, Nadezda, et al.
Publicado: (2019)

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

Alpha-PET for Prostate Cancer: Preclinical investigation using (149)Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms
por: Borgna, Francesca, et al.
Publicado: (2021)

Precise activity measurements of medical radionuclides using an ionization chamber: a case study with Terbium-161
por: Juget, Frédéric, et al.
Publicado: (2022)

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
por: Haller, Stephanie, et al.
Publicado: (2016)

Dosimetric Analysis of the Short-Ranged Particle Emitter (161)Tb for Radionuclide Therapy of Metastatic Prostate Cancer
por: Bernhardt, Peter, et al.
Publicado: (2021)

Simultaneous Visualization of (161)Tb- and (177)Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
por: Borgna, Francesca, et al.
Publicado: (2021)

Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics
por: Müller, Cristina, et al.
Publicado: (2016)

Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application
por: Müller, Cristina, et al.
Publicado: (2018)

Establishment of a clinical SPECT/CT protocol for imaging of (161)Tb
por: Marin, I., et al.
Publicado: (2020)

Preclinical investigations and first-in-human application of $^{152}$Tb-PSMA-617 for PET/CT imaging of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Preclinical investigations and first-in-human application of (152)Tb-PSMA-617 for PET/CT imaging of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Terbium-149 for targeted alpha therapy
por: Borgna, Francesca, et al.
Publicado: (2021)

(161)Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of (161)Tb into the Clinic
por: Favaretto, Chiara, et al.
Publicado: (2023)

Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
por: Tschan, Viviane J., et al.
Publicado: (2021)

Albumin-Binding PSMA Radioligands: Impact of Minimal Structural Changes on the Tissue Distribution Profile
por: Deberle, Luisa M., et al.
Publicado: (2020)

Preclinical investigations using [(177)Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
por: Tschan, Viviane J., et al.
Publicado: (2022)

Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90
por: Hemmingsson, Jens, et al.
Publicado: (2022)

[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022)

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with $^152$Tb-DOTATOC
por: Baum, Richard P, et al.
Publicado: (2017)

Terbium-149 for targeted alpha therapy
por: Grundler, Pascal, et al.
Publicado: (2023)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Domnanich, Katharina, et al.
Publicado: (2014)

Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Airaksinen, A, et al.
Publicado: (2016)

Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute
por: Müller, Cristina, et al.
Publicado: (2019)

Terbium Radionuclides for Theranostics Applications: A Focus On MEDICIS-PROMED
por: Formento Cavaiera, R, et al.
Publicado: (2020)

Prospects in Folate Receptor-Targeted Radionuclide Therapy
por: Müller, Cristina, et al.
Publicado: (2013)

Cyclotron production and radiochemical purification of terbium-155 for SPECT imaging
por: Favaretto, C., et al.
Publicado: (2021)

Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity
por: Deberle, Luisa M., et al.
Publicado: (2020)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Köster, Ulli
Publicado: (2017)

IS528 Novel diagnostic and therapeutic radionuclides for the development of innovative radiopharmaceuticals
por: Koester, Ulli, et al.
Publicado: (2018)

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
por: Lütje, Susanne, et al.
Publicado: (2015)

Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability
por: Cassells, Irwin, et al.
Publicado: (2021)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach
por: Kgatle, Mankgopo M., et al.
Publicado: (2021)

A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in Mice
por: Pellegrini, Giovanni, et al.
Publicado: (2017)

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
por: Szponar, Paweł, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3cu6grflf3eik57or3cd385vpa